We are live on ! Find out more
GPCR icon

Structure Therapeutics

84 hedge funds and large institutions have $1.64B invested in Structure Therapeutics in 2023 Q3 according to their latest regulatory filings, with 42 funds opening new positions, 29 increasing their positions, 6 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

600% more first-time investments, than exits

New positions opened: 42 | Existing positions closed: 6

383% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 6

175% more funds holding in top 10

Funds holding in top 10: 411 (+7)

135% more capital invested

Capital invested by funds: $699M → $1.64B (+$944M)

75% more funds holding

Funds holding: 4884 (+36)

14.1% more ownership

Funds ownership: 16.43%30.53% (+14%)

Holders
84
Holders Change
+36
Holders Change %
+75%
% of All Funds
1.33%
Holding in Top 10
11
Holding in Top 10 Change
+7
Holding in Top 10 Change %
+175%
% of All Funds
0.17%
New
42
Increased
29
Reduced
6
Closed
6
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
T. Rowe Price Associates
1
T. Rowe Price Associates
Maryland
$127M +$23.9M +740,213 +42%
DCM
2
Driehaus Capital Management
Illinois
$120M +$40.4M +1,252,940 +110%
Janus Henderson Group
3
Janus Henderson Group
United Kingdom
$97.5M +$64.9M +2,013,893 +2,601%
DTC
4
Deep Track Capital
Connecticut
$96.6M -$23.6M -731,782 -28%
Adage Capital Partners
5
Adage Capital Partners
Massachusetts
$90.8M +$51.8M +1,607,525 +836%
BI
6
BVF Inc
California
$88.2M
Fidelity Investments
7
Fidelity Investments
Massachusetts
$80.2M +$11.4M +352,600 +28%
T. Rowe Price Investment Management
8
T. Rowe Price Investment Management
Maryland
$79.2M +$29.6M +917,161 +140%
TCM
9
TCG Crossover Management
California
$75.8M +$37.1M +1,152,747 +329%
CC
10
Casdin Capital
New York
$62M +$8.42M +261,149 +26%
Federated Hermes
11
Federated Hermes
Pennsylvania
$56M +$3.08M +95,500 +9%
Citadel Advisors
12
Citadel Advisors
Florida
$54.5M +$23.6M +730,929 +209%
HH
13
HSG Holding
Hong Kong
$53.7M +$34.3M +1,065,226 New
CAM
14
Cormorant Asset Management
Massachusetts
$53.3M +$15.5M +480,000 +83%
ACA
15
Avoro Capital Advisors
New York
$50.4M +$32.2M +1,000,000 New
Wellington Management Group
16
Wellington Management Group
Massachusetts
$43.7M +$21.2M +657,310 +313%
Point72 Asset Management
17
Point72 Asset Management
Connecticut
$37.7M +$10.2M +316,100 +73%
MIM
18
Monashee Investment Management
Massachusetts
$32M -$23.8M -737,225 -54%
DM
19
Deerfield Management
New York
$31.7M
BlackRock
20
BlackRock
New York
$26.6M +$4.27M +132,484 +34%
LGM
21
Logos Global Management
California
$25.2M +$3.22M +100,000 +25%
APM
22
Avidity Partners Management
Texas
$25.2M +$14.9M +462,200 +1,223%
Jennison Associates
23
Jennison Associates
New York
$21.2M +$667K +20,699 +5%
FLAM
24
First Light Asset Management
Minnesota
$18.9M +$12.1M +374,412 New
Capital Research Global Investors
25
Capital Research Global Investors
California
$17.3M +$11.1M +344,848 New

GPCR Hedge Fund Activity: Q3 2023 in Review

84 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Structure Therapeutics (GPCR) for Q3 2023, worth a combined $1.64B — up 135% from $699M a quarter earlier.

Buyers outnumbered sellers: 42 funds opened new GPCR positions and 6 closed out — a net gain of 36 holders — while 29 added to existing stakes and 6 trimmed.

The largest buyer was Janus Henderson Group, adding an estimated $64.9M. The largest seller was Monashee Investment Management, cutting an estimated $23.8M.

  • 84 institutional investors held Structure Therapeutics (GPCR) as of Q3 2023, up from 48 in Q2 2023.
  • Funds reported $1.64B of Structure Therapeutics stock for Q3 2023, up 135% quarter-over-quarter.
  • 42 funds opened new Structure Therapeutics positions in Q3 2023 and 6 closed out, a net change of +36 holders.
  • The largest Structure Therapeutics buyer in Q3 2023 was Janus Henderson Group, an estimated $64.9M added.
  • The largest Structure Therapeutics seller in Q3 2023 was Monashee Investment Management, an estimated $23.8M sold.

Based on aggregated 13F filings for Q3 2023.